Elizabeth (Beth) Garner is a seasoned strategic- and business-minded pharmaceutical executive and corporate board member with a career-long focus on addressing unmet medical needs. Born and raised in Nigeria, she brings a global view to her leadership in both the corporate and non-profit worlds. Dr. Garner is currently the CEO of Sena Therapeutics, a start-up company focused on developing precision medicines for endocrine diseases. Most recently, she was US Chief Scientific Officer of Ferring Pharmaceuticals, a mid-size global company focused on reproductive and maternal health, microbiome and gastrointestinal therapeutics, and uro-oncology. Her prior C-suite roles include Chief Medical Officer of ObsEva and Agile Therapeutics. She has also held leadership roles at Myriad Genetics, Abbott Laboratories, and Merck Research Labs, where she was a contributor on the Gardasil and Gardasil9 vaccines. Dr. Garner is currently on the Board of Directors (BOD) of Kezar Life Sciences (KZR) and Sermonix Therapeutics, and is the BOD chair of NUA Surgical, a start-up company dedicated to creating innovative surgical solutions in obstetrics and gynecology. She is also a Past President of the American Medical Women’s Association (AMWA), a professional organization whose mission is to advance women physicians, advocate for equity, and ensure excellence in healthcare. Beth received joint M.D. and M.P.H. degrees from Harvard Medical and Public Health Schools, trained in obstetrics and gynecology at Brigham and Women’s (BWH)/Massachusetts General Hospitals, and completed a fellowship in gynecologic oncology at BWH/Dana Farber Cancer Institute.